Pirracchio Romain, Logeart Damien, Noveanu Markus, Mebazaa Alexandre, Mueller Christian
University Paris 7 Diderot, Department of Anesthesiology and Critical Care, Hôpital Lariboisière, Paris, France.
Curr Opin Crit Care. 2008 Oct;14(5):536-42. doi: 10.1097/MCC.0b013e32830c4875.
B-type natriuretic peptides are quantitative markers of heart failure (and/or cardiac stress) that summarize the extent of systolic and diastolic left ventricular dysfunction, valvular dysfunction, and right ventricular dysfunction. Based on the observation that heart failure is common albeit difficult to diagnose in the ICU, several studies have begun to evaluate the potential use of B-type natriuretic peptides in various ICU settings.
Previous pilot studies have examined the use of B-type natriuretic peptide in the differential diagnosis of hypoxemic respiratory failure, to differentiate cardiogenic from noncardiogenic shocks or to predict fluid responsiveness, to assess myocardial dysfunction and prognosis in patients with severe sepsis, and to predict ventilatory weaning failure.
Although previous studies were small, they highlight the potential of using B-type natriuretic peptides as a noninvasive easily available tool to quantify cardiac stress.
